Figure 3

Capmatinib has a broad range of antiviral activity against human coronaviruses. (A) Quantification of 229E Spike protein abundance in MRC-5 cells treated with increasing doses of capmatinib in the IF assay (48 h infection), as mean ± SE (n = 3) expressed relative to DMSO (vehicle) control. *P < 0.05 relative to control (B) (left) Representative images of 229E plaques observed in MRC-5 cells treated with 10 µM capmatinib or DMSO (vehicle) for 6 days. (right) Quantification of viral titer from the DMSO (vehicle) control or capmatinib plaque assays, expressed as PFU/mL. *P < 0.05 relative to control (C). (left) Representative images of NL63 plaques observed in LLC-MK2 treated with 10 µM capmatinib or DMSO (vehicle) control for 5 days. (right) Quantification of NL63 PFU/mL in LLC-MK2 cells treated with the indicated doses of capmatinib. *P < 0.05 relative to control (D). Relative NL63 N protein RNA abundance 3 days post-infection in LLC-MK2 cells treated with 10 µM capmatinib relative to DMSO (vehicle) control. *P < 0.05 relative to control, n = 3 experimental replicates. E (left) Representative images of OC43 plaques observed in LLC-MK2 cells treated with 10 µM capmatinib or DMSO (vehicle) for 5 days. (right) Quantification of OC43 PFU/mL in LLC-MK2 cells treated with capmatinib or DMSO (vehicle) control. *P < 0.05 relative to control.